Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.

摘要: AIM The aim of this study was to characterize quality buprenorphine care for opioid use disorder (OUD) by quantifying initiation, engagement, and maintenance individuals in a large, diverse, real-world cohort the United States. DESIGN This retrospective analysis. SETTING OUD treatment outpatient setting. PARTICIPANTS A total 45,210 commercially insured Medicare Advantage (MA) enrollees 18 years or older OptumLabs Data Warehouse with an index diagnosis between January 1, 2018 December 31, 2018. INTERVENTIONS Treatment buprenorphine. MEASUREMENTS We calculated 6 measures quality. conducted survival analyses duration logistic regressions evaluate association clinical sociodemographic characteristics FINDINGS Of eligible OUD, ∼1 10 (n=4600, 10.2%) initiated within 365 days following (Measure #1) 2850 (6.3%) 14 #2). initiating diagnosis, 1769 (62.1%) had 2 more claims 34 initiation #3). 4600 who received buprenorphine, 2300 (50.0%) were maintained 180 covered during after #4). Finally, 2543 (55.3%) did not fill any other concurrent analgesic #5) 2951 (64.2%) benzodiazepine #6). Quality generally lower MA compared commercial coverage among Hispanic Black adults White adults. CONCLUSION Widespread gaps exist OUD.